Clinical trials: Dementia Disorders
Preclinical Alzheimer's Disease
Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease
- Trial name
- SPINOZA (NCT07794670)
- Testing
- Obicetrapib 10 mg
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- NewAmsterdam Pharma
Dementia Associated With Cerebrovascular Disease
A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease
The primary objectives are to confirm that donepezil hydrochloride has superior efficacy compared with placebo in improving cognitive function, as measured by Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog)…
- Trial name
- NCT02660983
- Testing
- Donepezil hydrochloride
- Where
- 31 sites in South Korea
- Volunteers
- 302 people
- Sponsor
- Eisai Co., Ltd.
Alzheimer Dementia
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
This study is a multicenter, randomized, double-blind, double-dummy, active- and placebo-controlled, parallel-group clinical trial.
- Trial name
- NCT07066826
- Testing
- Huperzine A Controlled-Release Tablets, Donepezil hydrochloride tablets
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Wanbangde Pharmaceutical Group Co., LTD
Alzheimer Disease
ELND005 in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).
- Trial name
- NCT00568776
- Testing
- ELND005
- Where
- 62 sites in United States, Canada
- Volunteers
- 353 people
- Sponsor
- OPKO Health, Inc.
Parkinson's Disease Dementia
Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
The purpose of this study is to provide long-term safety data for rivastigmine capsule and transdermal patch treatments, in particular the effect of rivastigmine on worsening of the underlying motor symptoms of Parkinson's…
- Trial name
- NCT00623103
- Testing
- Rivastigmine capsule, Rivastigmine transdermal patch
- Where
- 127 sites in United States, Argentina and 11 more
- Volunteers
- 583 people
- Sponsor
- Novartis
Huntington Disease
Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease
This is the second study of AMT-130 in patients with early manifest HD and is designed as part of an integrated two-study phase I/II program under a single data safety monitoring board (DSMB) with staggered enrollment based upon…
- Trial name
- NCT05243017
- Testing
- intra-striatal rAAV5-miHTT
- Where
- 4 sites in Poland, United Kingdom
- Volunteers
- 14 people
- Sponsor
- UniQure Biopharma B.V.
Alzheimer's Disease, Dementia
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of NIC5-15 in the treatment of Alzheimer's Disease.
- Trial name
- NCT01928420
- Testing
- Drug: NIC5-15
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Humanetics Corporation
Alzheimer's Disease
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
The purpose of this study is to evaluate the effects of PF-04447943 compared to placebo on cognitive, behavioral and overall symptoms of Alzheimer's disease; evaluate the safety and tolerability of PF-0444793 compared to placebo…
- Trial name
- NCT00930059
- Testing
- PF-04447943
- Where
- 44 sites in United States, Canada and 2 more
- Volunteers
- 191 people
- Sponsor
- Pfizer
Alzheimer's Disease
Safety and Efficacy of MT-4666
The objective of this study is to evaluate the safety and efficacy as assessed by the Alzheimers Disease Assessment Scale-cognitive subscale 13-item (ADAS-cog-13) of two doses of MT-4666 or placebo administered daily for 24 weeks…
- Trial name
- NCT01764243
- Testing
- MT-4666
- Where
- Japan
- Volunteers
- 450 people
- Sponsor
- Tanabe Pharma Corporation
Herpes Zoster
A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland
The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland.
- Trial name
- NCT07502560
- Testing
- Recombinant zoster vaccine
- Where
- 8 sites in Finland
- Volunteers
- 33,609 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers, Alzheimer Disease
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
The purpose of this study is to see how safe LY4560736 is and to see how much and how quickly LY4560736 gets into the bloodstream. For healthy participants, the study also looks at how much LY4560736 gets into the brain.
- Conditions
- Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
- Trial name
- NCT07843459
- Testing
- LY4560736, Florbetapir F18, Florbetaben F 18
- Where
- 18 sites in United States, China and 1 more
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease, Dementia
Webnovela for Hispanic Dementia Family Caregivers
Photozig and Stanford University are creating a new program for Hispanic dementia caregivers to help cope with caregiving, alleviate related stress, and enhance quality of life for caregivers, with funding from the National…
- Trial name
- NCT02489110
- Testing
- Webnovela, Information
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Photozig, Inc.
Frontotemporal Dementia
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts…
- Trial name
- NCT05262023
- Testing
- DNL593
- Where
- 26 sites in United States, Belgium and 10 more
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Denali Therapeutics Inc.
Alzheimer's Disease
Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease
This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease. This study also will examine the safety and tolerability of the drug.
- Trial name
- NCT00842673
- Testing
- ST101
- Where
- 18 sites in United States, Canada
- Volunteers
- 168 people
- Sponsor
- Sonexa Therapeutics, Inc.
COPD Symptoms After Coil Procedure
Chronic Obstructive Pulmonary Disease (COPD) Co-Pilot AIR Substudy of CLN0014
The purpose of undertaking CLN0020, which was a Substudy of the European Coil registry (CLN0014), was to investigate the use of COPD Co-Pilot AIR™, a COPD disease management program manufactured and operated by HGE Health Care…
- Trial name
- Co-Pilot Air (NCT03267992)
- Testing
- COPD Co-Pilot AIR App
- Where
- 2 sites in Switzerland
- Volunteers
- 9 people
- Sponsor
- Boston Scientific Corporation
Amyotrophic Lateral Sclerosis
A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)
Protocol PL101-ALS501: This EAP will provide access to pridopidine for up to 200 patients with ALS who are ineligible for clinical trials.
- Trial name
- NCT06069934
- Testing
- Pridopidine
- Where
- 32 sites in United States, Puerto Rico
- Sponsor
- Prilenia
Healthy Volunteers, Alzheimer Disease
A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease
This study involves single and multiple doses of LY3202626 and will evaluate the effects of LY3202626 on the body. There will be 4 parts to this study.
- Trial name
- NCT02323334
- Testing
- LY3202626, Itraconazole
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
This is a multicenter, double-blind, placebo controlled, randomized, outpatient multiple dose study in male and female patients ages 50 to less than 89 years with mild to moderate AD.
- Trial name
- NCT00574132
- Testing
- Bapineuzumab 0.5 mg/kg, Bapineuzumab 1.0 m/kg
- Where
- 251 sites in United States, Austria and 2 more
- Volunteers
- 1,331 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Chorea, Huntington
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.
- Trial name
- NCT04400331
- Testing
- Valbenazine
- Where
- 34 sites in United States, Canada
- Volunteers
- 154 people
- Sponsor
- Neurocrine Biosciences
Alzheimer's Disease
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of…
- Trial name
- MissionAD1 (NCT02956486)
- Testing
- Elenbecestat
- Where
- 258 sites in United States, Argentina and 16 more
- Volunteers
- 2,212 people
- Sponsor
- Eisai Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.